DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for sea-blue histiocyte syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSea-blue histiocyte syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for sea-blue histiocyte syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
apolipoprotein E (APOE) — APOE is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8AX9 · 1.549 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Seven patients on long-term total parenteral nutrition after extensive short-bowel resection developed bone marrow sea-blue histiocytosis. Clinical abnormalities included hepatosplenomegaly and peripheral blood cytopenia, appearing at a median of 64 months. The bone marrow contained pigment-laden histiocytes with the typical morphology of sea-blue histiocytes seen in the idiopathic syndrome. The authors state this association had not been reported previously.
A 1973 letter notes that the primary syndrome of the sea-blue histiocyte had been reported with increasing frequency, both as a primary disorder and in association with a variety of diseases. The author refers to proposed criteria for diagnosing the primary syndrome and distinguishing it from secondary forms.
A 1980 letter reports a new case of the hereditary syndrome in which, for the first time, intestinal mucosa involvement was verified, with pronounced infiltration by sea-blue histiocytes. Over 70 cases of the primary and often familial disease had been published by then, affecting liver, spleen, and bone marrow. Sea-blue histiocytes had also been identified in patients with a variety of haematologic and metabolic abnormalities.
No treatment is tested or proposed in any of these abstracts. No drug is mentioned. What is missing is any controlled trial, any molecular characterisation of the stored lipid, any genetic linkage, and any systematic effort to distinguish primary from secondary cases by a validated biomarker rather than clinical context.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
British Journal of Haematology · 1996 · 36 citations · open access
Sea‐blue histiocyte syndrome in bone marrow secondary to total parenteral nutrition including fat‐emulsion sources: a clinicopathologic study of seven cases
AbstractBone marrow examination revealed a lipid-laden histiocytosis in seven patients undergoing long-term total parenteral nutrition necessitated by extensive short-bowel surgical resection. Clinical abnormalities occurred during this treatment which required bone marrow examination. These included hepatosplenomegaly and peripheral blood cytopenia; the median time to the detection of these abnormalities was 64 months. The most striking change within the bone marrow was the presence of many pigment-laden histiocytes which had the typical morphology of sea-blue histiocytes seen in the so-called idiopathic sea-blue histiocyte syndrome. The occurrence of sea-blue histiocytosis in the bone marrow in association with long-term parenteral nutrition for short-bowel syndrome has not, to our knowledge, been reported previously and should now be considered in the differential diagnosis of bone marrow sea-blue histiocytosis.
Familial Sea-Blue Histiocytes With Acid Phosphatemia
AbstractThree siblings with splenomegaly, peripheral neuropathy, café au lait spots, and elevated serum acid phosphatase level also had multiple sea-blue histiocytes apparent on bone marrow examination. Elevated bone marrow acid phosphatase level and abnormal histiocytes were found in the father. There is a relationship of this new syndrome to other conditions associated with sea-blue histiocytes.
Abstract<h3>To the Editor.—</h3> In the recent paper "Familial Sea-Blue Histiocytosis" by Blankenship et al (225:54, 1973), the authors observed that the syndrome of the sea-blue histiocyte has been reported with increasing frequency, both as a primary disorder and in association with a variety of diseases; but they do not mention the article that brought the attention of this cell to the medical public.<sup>1</sup>In their discussion the authors quote a letter to the editor by Kattlove et al<sup>2</sup>but nowhere do they give our reply to Dr. Kattlove's letter. Dr. Reynolds wrote to me on May 4, 1972, requesting my thoughts regarding the patients that they subsequently described. I told them that in a subsequent paper<sup>3</sup>we would (and did) suggest succinct criteria for the diagnosis of the primary syndrome of the sea-blue histiocyte and ways in which the primary syndrome might be distinguished from the numerous
Archives of Internal Medicine · 1980 · 0 citations
Sea-Blue Histiocytosis: A New Cause of Malabsorption Syndrome?
AbstractTo the Editor. —Since the first description of Silverstein et al 1 in 1970 of the syndrome of the sea-blue histiocyte, over 70 cases of the primary and often familial disease have been published in world literature. All of them characteristically affect diverse organs of the reticuloendothelial system, principally liver, spleen, and bone marrow, and deal with more or less common symptoms. 2 Other than in the hereditary syndrome, sea-blue histiocytes have been identified in bone marrow or spleen of patients with an impressive variety of hematologic and metabolic abnormalities. 3 In 1972, Silverstein and Ellefson 4 had proposed criteria for the diagnosis of the primary form of the sea-blue histiocytosis. We have recently been able to study a new case of the hereditary syndrome in which, for the first time, the involvement of the intestinal mucosa has been verified, having observed a pronounced infiltration by sea-blue histiocytes in its
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
